A persuasive BV pattern can explain vaginal odor without closing the STI workup. In an illustrative case, a 24-year-old has a week of thin, fishy discharge, a new partner, inconsistent condom use, and no STI screening in over a year. Her discharge, pH of 5.5, positive amine odor with KOH, and clue cells fit all four Amsel criteria for bacterial vaginosis (BV). But those findings do not test for chlamydia or gonorrhea, and a wet mount without visible trichomonads does not reliably exclude trichomoniasis.
The useful family-medicine question is not simply, “BV or STI?” It is: What explains the vaginal symptoms, and what separate infection testing is still warranted today?
One bedside diagnosis, two clinical questions
Amsel criteria support a clinical diagnosis of BV when at least three of four findings are present: thin, homogeneous discharge; clue cells; vaginal pH above 4.5; and a fishy amine odor before or after KOH is added. This patient meets all four.
That diagnosis answers the vaginitis question. It does not establish whether the patient has an STI, when a particular infection was acquired, or whether a partner transmitted it. A new partner is a reason to ask about exposure and testing—not evidence of transmission or infidelity.
| Finding | What it supports | What it does not establish |
|---|---|---|
| Thin discharge, elevated pH, amine odor, and clue cells | BV by clinical Amsel criteria | Absence of a coexisting STI |
| Normal-appearing cervix and no cervical motion tenderness | No documented cervical inflammation or pelvic tenderness on this exam | Negative chlamydia or gonorrhea tests |
| No motile trichomonads on wet mount | None were seen on the slide | That trichomoniasis is absent |
Chlamydia and gonorrhea can be asymptomatic. The absence of mucopurulent cervical discharge, friability, pelvic pain, or cervical motion tenderness lowers concern for clinical cervicitis or PID in this presentation, but it is not a substitute for indicated testing.
Close the testing gap without undoing the diagnosis
At age 24, a sexually active patient is due for annual chlamydia and gonorrhea screening even if she has no symptoms. A new partner and inconsistent condom use make a current sexual history especially important. Order NAAT for both infections; a vaginal specimen is an appropriate urogenital option. Ask about oral or anal exposure as part of a nonjudgmental history and consider site-specific testing when indicated.
Do not let the negative wet mount settle the trichomoniasis question. Testing for Trichomonas vaginalis is recommended for women seeking care for vaginal discharge. Wet-mount microscopy has limited sensitivity, so a negative slide can miss infection; use a sensitive molecular test when available, particularly when exposure history or persistent symptoms keep suspicion alive.
Complete the rest of the sexual-health assessment as well. Include HIV testing if status is unknown, and assess whether repeat testing is indicated by ongoing exposure risk and timing. CDC guidance also recommends HIV and other STI testing for women with BV. Decide whether syphilis or additional testing is appropriate from the patient’s history, exposures, and local epidemiology rather than assuming every new partner creates the same testing indication.
A negative pelvic exam is not a reason to skip tests that are otherwise due. Conversely, the new-partner history alone does not diagnose an STI or PID. Collect the appropriate tests, explain what is being tested, and make a clear plan for communicating results and arranging treatment if needed.
Treat the symptoms and keep the results in view
Because the patient is symptomatic and meets Amsel criteria, BV treatment can begin while STI testing is pending. One recommended option is metronidazole 500 mg orally twice daily for seven days; intravaginal metronidazole or clindamycin are alternatives. Choose a regimen with the patient, taking preferences and relevant contraindications into account.
The important management distinction is that a BV diagnosis—and a prescription selected for BV—is not a complete STI-management plan. Metronidazole does not treat chlamydia or gonorrhea. If another test is positive, follow the relevant pathogen-specific treatment and follow-up pathway; if trichomoniasis is identified, address partner management as well.
Arrange follow-up in a way that fits the patient’s situation: confirm how results will be delivered, whether the patient can be reached confidentially, and what to do if symptoms persist or worsen. New pelvic pain, fever, or increasing tenderness calls for reassessment rather than simply repeating the BV treatment.
Common traps
- Stopping at the first good explanation. BV may explain the odor and discharge, but it does not rule out a concurrent infection.
- Treating the wet mount as a perfect exclusion test. Not seeing trichomonads is not the same as a negative sensitive molecular test.
- Reading a normal cervix as a negative STI screen. Examination findings and NAAT answer different questions.
- Inferring a source from timing. A new partner is a risk-history detail, not proof of when or how BV or an STI began.
- Assuming BV treatment covers every possibility. Review the STI results and act on them separately.
Practical takeaways
- Use Amsel criteria to support symptomatic BV; do not make a supportive microscopy finding a required criterion.
- Keep the vaginal-symptom diagnosis separate from the sexual-health testing decision.
- In a sexually active patient younger than 25, order due chlamydia and gonorrhea screening; test for trichomoniasis when evaluating vaginal discharge, even if the wet mount is negative.
- Offer HIV testing if status is unknown, and tailor additional STI tests to exposure history and local epidemiology.
- Treat BV symptoms, communicate test results reliably, and reassess promptly if pelvic symptoms develop.
